| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H10Cl2N2O |
| Molecular Weight | 245.105 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(OCC2=NCCN2)C=C1Cl
InChI
InChIKey=FVHAONUKSUFJKN-UHFFFAOYSA-N
InChI=1S/C10H10Cl2N2O/c11-8-2-1-7(5-9(8)12)15-6-10-13-3-4-14-10/h1-2,5H,3-4,6H2,(H,13,14)
| Molecular Formula | C10H10Cl2N2O |
| Molecular Weight | 245.105 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Fenmetozole is an alpha-2 adrenergic receptor antagonist which was developed for the treatment of schizophrenic and/or depressed patients, however never reached the market. It was also shown that the drug may reduce symptoms of minimal brain dysfunction in children and antagonize the effect of barbiturates and ethanol.
CNS Activity
Originator
Approval Year
Doses
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Sourcing
PubMed
Patents
Sample Use Guides
Administer 250 to 450 milligrams of fenmetozole hydrochloride per day for 3-4 weeks (schizophrenic and/or depressed patients) or orally at a daily dosage rate of about 3 mg/kg/day using three divided dosages (in children with Minimal Brain Dysfunction).
Route of Administration:
Oral
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
